Molecular Partners AG ADR (MOLN) Stock Analysis

Molecular Partners AG ADR (MOLN) is a publicly traded company in the HEALTHCARE sector. It trades at $4.07, carries a market capitalization of $157.54M. This page summarizes the public market data, fundamentals, and frequently asked questions for MOLN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Molecular Partners AG ADR currently has a Bullish sentiment score of 0.30.

About Molecular Partners AG ADR

Molecular Partners AG (MOLN) is an innovative clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focusing on the development of novel protein-based therapeutics targeting oncology and viral infections. The company leverages its proprietary Darpin and Drug Conjugate technology platforms to design targeted therapies that enhance efficacy while minimizing side effects. With a promising clinical pipeline aimed at addressing critical unmet medical needs, Molecular Partners i...

GNG Research Analysis

GNG Research scores Molecular Partners AG ADR (MOLN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MOLN.

Frequently Asked Questions

Does MOLN pay dividends?

Molecular Partners AG ADR (MOLN) does not currently pay a regular dividend.

What is MOLN's market cap?

Molecular Partners AG ADR (MOLN) has a market capitalization of $157.54M with a current stock price of $4.07.